1564252-97-6

Basic information

• Product Name: C₁₅H₁₁ClN₄O
• Synonyms: C₁₅H₁₁ClN₄O
• CAS NO: 1564252-97-6
• Molecular Weight: 298.732
• Mol File: 1564252-97-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₁₅H₁₁ClN₄O(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₅H₁₁ClN₄O(1564252-97-6)
• EPA Substance Registry System: C₁₅H₁₁ClN₄O(1564252-97-6)

Safety Data

• Hazardous Substances Data: 1564252-97-6(Hazardous Substances Data)

Upstream product

• 4198-90-7 3,5-dimethyl-4-hydroxybenzonitrile 
• 57489-77-7 5,7-dichloropyrazolo[1,5-a]pyrimidine 
• 672323-32-9 pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione 

Downstream Products

• 1564252-79-4 4-(5-(4-cyanophenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 
• 1564252-80-7 4-(5-(4-bromophenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 
• 1564252-81-8 4-(5-(4-chlorophenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 
• 1564252-85-2 4-(5-(4-nitrophenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 
• 1564252-84-1 4-(5-(4-methoxyphenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 
• 1564252-83-0 4-(5-(4-methylphenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 
• 1564252-82-9 4-(5-(4-fluorophenylamino)pyrazolo[1,5-a]pyrimidin-7-yloxy)-3,5-dimethylbenzonitrile 

Relevant articles and documents

Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives

In our continuous efforts to identify novel potent HIV-1 NNRTIs, a novel class of 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives were rationally designed, synthesized and evaluated for their anti-HIV activities in MT4 cell cultures. Biological results showed that most of the tested compounds displayed excellent activity against wild-type HIV-1 with a wide range of EC50 values from 5.98 to 0.07 μM. Among the active compounds, 5a was found to be the most promising analogue with an EC50 of 0.07 μM against wild-type HIV-1 and very high selectivity index (SI, 3999). Compound 5a was more effective than the reference drugs nevirapine (by 2-fold) and delavirdine (by 2-fold). In order to further confirm their binding target, an HIV-1 RT inhibitory assay was also performed. Furthermore, SAR analysis among the newly synthesized compounds was discussed and the binding mode of the active compound 5a was rationalized by molecular modeling studies.